Conferences - Results from #40

ASCO 2023: Treatment and Survival of De Novo mHSPC Among African American US Veterans June 3, 2023

ASCO 2023: PSMA Expression and Response to 177Lu-PSMA-617 in Men with vs. Without DNA Damage Repair Mutations June 3, 2023

ASCO 2023: MAIN-CAV: Phase III Randomized Trial of Maintenance Cabozantinib and Avelumab Versus Avelumab After First-Line Platinum-Based Chemotherapy in Patients with Metastatic Urothelial Cancer June 3, 2023

ASCO 2023: PSMA PET Findings in an “EMBARK-like” Cohort of Patients with High-Risk Non-Metastatic Hormone-Sensitive Prostate Cancer: A Single Center Post-Hoc Retrospective Analysis June 3, 2023

ASCO 2023: The Relationship Between a Priori Defined Prognostic Risk Groups and Overall Survival in Men with mHSPC June 3, 2023

ASCO 2023: Adjuvant Everolimus in Patients with Localized Non-Clear Cell Renal Cell Carcinoma: Subgroup Analysis from the EVEREST Trial June 3, 2023

ASCO 2023: Nivolumab plus Cabozantinib in Patients with Non-Clear Cell Renal Cell Carcinoma: Updated Results from a Phase 2 Trial June 3, 2023

ASCO 2023: Core Biopsy Accuracy and Safety of Biopsy and Preoperative Immunotherapy in Predicting Histological Subtype and Nuclear Grade in ECOG-ACRIN EA8143 Perioperative Nivolumab Versus Observation in Patients with Kidney Cancer Undergoing Nephrectomy June 3, 2023

ASCO 2023: Characterizing Progression to Subsequent Lines of Therapy in Metastatic Renal Cell Carcinoma After Nivolumab plus Ipilimumab (Nivo+Ipi): Results from the IMDC June 3, 2023

ASCO 2023: ARASEC: Open-Label Study of Darolutamide Plus ADT vs ADT in mHSPC Using an External Control Arm June 3, 2023

ASCO 2023: Phase 2 Study of Batiraxcept as Monotherapy, in Combination with Cabozantinib, and in Combination with Cabozantinib and Nivolumab in Patients with Advanced Clear Cell Renal Cell Carcinoma June 3, 2023

ASCO 2023: Assessing PSA Levels as Prognostic of Overall Survival in Men with mHSPC June 3, 2023

ASCO 2023: Head-to-Head Effectiveness and Safety of Pembrolizumab plus Axitinib vs. Nivolumab plus Ipilimumab in Metastatic Renal Cell Carcinoma in the United States June 3, 2023

ASCO 2023: CASSIOPE: A Prospective Noninterventional Study of Cabozantinib Treatment Following Prior Vascular Endothelial Growth Factor - Targeted Therapy in Patients with Advanced Renal Cell Carcinoma June 3, 2023

ASCO 2023: Health-Related Quality of Life (HRQoL) of Risk-Based Patient Subgroups with Advanced Renal Cell Cancer (aRCC) Treated with Nivolumab plus Cabozantinib vs Sunitinib in the CheckMate 9ER Trial June 3, 2023

ASCO 2023: DEAR: Comparative Real-World Evidence on Darolutamide, Enzalutamide, and Apalutamide for Patients with nmCRPC in the United States June 3, 2023

ASCO 2023: A Phase I/II Study to Evaluate the Safety, Pharmacodynamics, and Efficacy of Entinostat in Combination with Atezolizumab and Bevacizumab in Patients with Renal Cell Carcinoma June 3, 2023

ASCO 2023: Biomarker-Driven Prospective Clinical Trial in Renal Cell Carcinoma: Developing Machine Learning Models to Allocate Patients to Treatment Arms Using RNA Sequencing June 3, 2023

ASCO 2023: Determinants of Resistance to Nivolumab Monotherapy Investigated Through Genomic and Transcriptomic Analysis of Renal Cell Carcinoma Tumors from the HCRN GU16-260 Study June 3, 2023

ASCO 2023: Darolutamide and Time to Pain Progression by Disease Volume In ARASENS June 3, 2023

Page 3 of 518